Literature DB >> 23513469

Efficacy of fresh lime for smoking cessation.

Suthat Rungruanghiranya1, Chatchai Ekpanyaskul, Chanin Sakulisariyaporn, Prapada Watcharanat, Kunyanit Akkalakulawas.   

Abstract

OBJECTIVE: To determine the efficacy of fresh lime as a smoking cessation aid compared with nicotine gum. MATERIAL AND
METHOD: A randomized, controlled trial was conducted between March 2009 and September 2009. Only regular smokers aged 18 or older who were willing to quit were randomized to receive either fresh lime (n = 47) or nicotine gum (n = 53). Smokers were excluded if they were using other smoking cessation aids, allergic to citrus, or had dental problems. Exhaled carbon monoxide (CO)-confirmed continuous abstinence rate (CAR) during week 9-12 was measured as the primary outcomes. To grade the severity of craving, a 100-mm visual analogue scale (VAS) was used.
RESULTS: There was no significant difference in CO-confirmed CAR between the fresh lime group and the nicotine gum group during weeks 9-12 (61.7% vs. 66.0%; p = 0.65), although 7-day point prevalence abstinence at week 4 of the fresh lime users was statistically significant lower than those using nicotine gum (38.3% vs. 58.5%; p = 0.04). Cravings did not differ significantly between the groups, although fresh lime users tend to report more cravings intensity.
CONCLUSION: Fresh lime can be used effectively as a smoking cessation aid, although not as good as nicotine gum in reducing cravings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23513469

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  2 in total

Review 1.  Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.

Authors:  Joshua L Karelitz; Erin A McClure; Caitlin Wolford-Clevenger; Lauren R Pacek; Karen L Cropsey
Journal:  Drug Alcohol Depend       Date:  2021-02-03       Impact factor: 4.492

2.  Evidence-based new service package vs. routine service package for smoking cessation to prevent high risk patients from cardiovascular diseases (CVD): study protocol for randomized controlled trial.

Authors:  Myo Nyein Aung; Motoyuki Yuasa; Thaworn Lorga; Saiyud Moolphate; Hiroshi Fukuda; Tsutomu Kitajima; Hirohide Yokokawa; Kazuo Minematsu; Susumu Tanimura; Yoshimune Hiratsuka; Koichi Ono; Prissana Naunboonruang; Payom Thinuan; Sachio Kawai; Yaoyanee Suya; Somboon Chumvicharana; Eiji Marui
Journal:  Trials       Date:  2013-12-05       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.